This inventor holds 56 USPTO granted patents and 11 published patent applications, plus 10 CIPO patents and 17 EPO patents, primarily in RNA Delivery (CPC class C12N). Top assignees: Arcturus Therapeutics, Inc., Nitto-Denko Corporation, Merck Sharp + Dohme Corp.. Active years: 2009-2026.
Inventors with similar research interests:
Location History:
- Oceanside, CA (US) (2009 - 2021)
- San Diego, CA (US) (2016 - 2023)
Company Filing History:
34 out of 65 
17 out of 3,941 
3 out of 2,405 
Years Active: 2009-2026
Areas of Expertise:
Title: Innovations by Joseph E. Payne: A Leader in RNA Nanoparticle Technology
Introduction: Joseph E. Payne, an accomplished inventor based in San Diego, CA, holds an impressive portfolio of 52 patents. His work primarily focuses on the development of innovative technologies in the field of biotechnology, particularly concerning RNA nanoparticles.
Latest Patents: One of Joseph's most recent patents is a method for producing lipid-encapsulated RNA nanoparticles. This intricate process involves several key steps: firstly, an aqueous solution containing RNA is flowed through a tube, designated as the 1-tube. Secondly, an ethanol solution comprising cationic lipids is introduced through a second tube, the 2-tube, at a specific flow rate relative to the aqueous solution. Lastly, both solutions are mixed within a specialized module that allows for the creation of a turbulent flow, resulting in lipid-encapsulated RNA nanoparticles with a bilayer structure. This cutting-edge approach has significant implications for drug delivery and therapeutic applications.
Career Highlights: Joseph E. Payne has garnered experience working with leading biotechnology companies, including Arcturus Therapeutics, Inc. and Nitto Denko Corporation. His innovative contributions have not only advanced the field of RNA technology but have also positively impacted various therapeutic developments.
Collaborations: Throughout his career, Joseph has collaborated with notable professionals such as Padmanabh Chivukula and Victor Knopov. These partnerships have further enriched his research initiatives and contributed to his success in the domain of nanoparticle technology.
Conclusion: Joseph E. Payne stands out as a prominent figure in the realm of innovations involving RNA nanoparticles. His extensive patent portfolio and collaborations with esteemed companies and colleagues reflect his commitment to advancing biotechnological solutions that hold the potential to transform medical therapies. His expertise and innovative spirit will undoubtedly pave the way for future breakthroughs in the industry.